NCT05672537 2023-01-05
Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
Tianjin Medical University Cancer Institute and Hospital
Tata Memorial Hospital
The First Affiliated Hospital of Zhengzhou University
Delcath Systems Inc.
Sun Yat-sen University
Benaroya Research Institute
Zhejiang University
Sun Yat-sen University
Tianjin Medical University Cancer Institute and Hospital
Fudan University
Shanghai Zhongshan Hospital